Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients

• Main Authors: Zaima Mazorra (Author), Anabel Lavastida (Author), Fernando Concha-Benavente (Author), Anet Valdés (Author), Raghvendra M. Srivastava (Author), Tatiana M. García-Bates (Author), Esperanza Hechavarría (Author), Zuyen González (Author), Amnely González (Author), Martha Lugiollo (Author), Iván Cuevas (Author), Carlos Frómeta (Author), Braulio F. Mestre (Author), Maria C. Barroso (Author), Tania Crombet (Author), Robert L. Ferris (Author)
• Format: Book
• Published: Frontiers Media S.A., 2017-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Survival benefit and long-term duration of clinical response have been seen using the epidermal growth factor receptor (EGFR)-targeted monoclonal antibody (mAb) nimotuzumab. Blocking EGFR signaling may not be the only mechanism of action underlying its efficacy. As an IgG1 isotype mAb, nimotuzumab&#...